Alnylam Reports 81% Full-Year Revenue Growth and Profitable 2025, Unveils 2026 Pipeline Goals
Alnylam posted fourth-quarter net product revenues of $995 million and full-year 2025 revenues of $2.987 billion, up 121% and 81% respectively, and achieved GAAP and non-GAAP profitability. It set 2026 pipeline goals including four clinical readouts, three pivotal studies, three Phase 2 initiations and a $250 million manufacturing expansion.
1. Financial Results
In the fourth quarter of 2025, Alnylam achieved global net product revenues of $995 million, marking 121% year-over-year growth, and full-year revenues of $2.987 billion, an 81% increase over 2024. The company attained both GAAP and non-GAAP profitability for the first time, driven by strong sales of AMVUTTRA and ONPATTRO.
2. 2026 Pipeline Goals
Alnylam outlined its 2026 pipeline ambitions, targeting four clinical readouts, three ongoing pivotal studies, three Phase 2 study initiations and more than three new IND filings. These programs span indications including ATTR-CM, type 2 diabetes, obesity and other rare diseases.
3. Manufacturing Expansion
The company plans to invest $250 million in a dedicated enzymatic-ligation siRNA manufacturing facility in Norton, Massachusetts. The siRELIS™ platform is designed to expand production capacity, lower costs and support future launches across its growing RNAi portfolio.
4. Strategic Outlook and Events
Under its new 'Alnylam 2030' strategy, the company aims for durable TTR leadership, sustainable innovation and disciplined growth. Alnylam reiterated its 2026 net product sales guidance and will host an investor webinar on March 24, 2026 to mark AMVUTTRA’s one-year ATTR-CM milestone and discuss long-term growth plans.